---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-24-000008"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:15:59.965368+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience raises $46.2M, sells real estate; equity now $49M for Nasdaq compliance

## Summary
- Net proceeds of ~$46.2M from private placement of 11.7M shares and pre-funded warrants on Jan 31, 2024.
- Subsidiary Avalite Sciences sold real estate on Jan 19, 2024, contributing ~$1.14M gain to equity.
- Pro forma stockholders' equity as of Sept 30, 2023 adjusted to $49.05M from $1.70M.
- Company believes equity now exceeds $5M minimum required for initial listing on The Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001516551-24-000008
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000008/0001516551-24-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000008/skye-20240212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-24-000008
- JSON: https://secwatch.observer/filing/0001516551-24-000008.json
- Plain text: https://secwatch.observer/filing/0001516551-24-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.